Merck Korea makes contract with LG to market new drugMerck Korea, the local unit of German pharmaceutical and chemical company Merck, said yesterday that it has signed a deal with LG Life Sciences, a biopharmaceutical company, to exclusively market and sell LG’s drug Rovatitan Tab, a treatment for hypertension and hyperlipidemia.
Michael Grund, managing director of Merck Korea, said, “Compared with valsartan monotherapy, Rovatitan Tab has additional blood pressure lowering effects, resulting in a strong synergy in blood pressure lowering and its powerful lipidemia improvement effects can minimize cardiovascular risk.”
More in Industry
Hyundai Motor is new darling of the stock market
Doosan Tower sells for 800 billion won as financial woes continue
Hyundai E&C wins big rail project contract in Philippines
Spud sundaes and ugly apples as retailers rush to help farmers